Bio-Techne Corporation
Bio-Techne Corporation Fundamental Analysis
Bio-Techne Corporation (TECH) shows weak financial fundamentals with a PE ratio of 109.69, profit margin of 6.67%, and ROE of 4.10%. The company generates $1.2B in annual revenue with moderate year-over-year growth of 5.23%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 44.7/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze TECH's fundamental strength across five key dimensions:
Efficiency Score
WeakTECH struggles to generate sufficient returns from assets.
Valuation Score
WeakTECH trades at a premium to fair value.
Growth Score
ModerateTECH shows steady but slowing expansion.
Financial Health Score
ExcellentTECH maintains a strong and stable balance sheet.
Profitability Score
WeakTECH struggles to sustain strong margins.
Key Financial Metrics
Is TECH Expensive or Cheap?
P/E Ratio
TECH trades at 109.69 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, TECH's PEG of 27.42 indicates potential overvaluation.
Price to Book
The market values Bio-Techne Corporation at 4.42 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 38.52 times EBITDA. This signals the market has high growth expectations.
How Well Does TECH Make Money?
Net Profit Margin
For every $100 in sales, Bio-Techne Corporation keeps $6.67 as profit after all expenses.
Operating Margin
Core operations generate 9.62 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $4.10 in profit for every $100 of shareholder equity.
ROA
Bio-Techne Corporation generates $3.21 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Bio-Techne Corporation produces operating cash flow of $250.30M, showing steady but balanced cash generation.
Free Cash Flow
Bio-Techne Corporation generates strong free cash flow of $223.90M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $1.43 in free cash annually.
FCF Yield
TECH converts 2.48% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
109.69
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
27.42
vs 25 benchmark
P/B Ratio
Price to book value ratio
4.42
vs 25 benchmark
P/S Ratio
Price to sales ratio
7.35
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.17
vs 25 benchmark
Current Ratio
Current assets to current liabilities
4.54
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.04
vs 25 benchmark
ROA
Return on assets percentage
0.03
vs 25 benchmark
ROCE
Return on capital employed
0.05
vs 25 benchmark
How TECH Stacks Against Its Sector Peers
| Metric | TECH Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 109.69 | 29.43 | Worse (Expensive) |
| ROE | 4.10% | 800.00% | Weak |
| Net Margin | 6.67% | -20145.00% (disorted) | Weak |
| Debt/Equity | 0.17 | 0.30 | Strong (Low Leverage) |
| Current Ratio | 4.54 | 4.64 | Strong Liquidity |
| ROA | 3.21% | -17936.00% (disorted) | Weak |
TECH outperforms its industry in 2 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Bio-Techne Corporation's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
60.16%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
-68.95%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
35.93%
Industry Style: Defensive, Growth, Innovation
High Growth